Updates of mTOR inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, proliferation, metabolism, and angiogenesis.
• Dysregulation of mTOR signaling is frequently observed in various human diseases, particularly cancer.
• mTOR functions through two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).

Purpose of the Study:

• To summarize current findings on the mTOR signaling pathway.
• To review updated data on mTOR inhibitors as potential anticancer agents.
• To discuss different classes of mTOR inhibitors and their mechanisms of action.

Main Methods:

• Literature review of preclinical and clinical studies on mTOR inhibitors.
• Analysis of drug mechanisms, including rapalogs and ATP-competitive inhibitors.
• Examination of the role of natural products as mTOR inhibitors.

Main Results:

• Rapalogs selectively inhibit mTORC1 and have shown efficacy in preclinical cancer models and clinical trials.
• A new generation of mTOR inhibitors targets the ATP-binding site, inhibiting both mTORC1 and mTORC2 with high selectivity.
• Natural products like EGCG, caffeine, curcumin, and resveratrol also exhibit mTOR inhibitory effects.

Conclusions:

• mTOR signaling is a critical target for cancer therapy.
• Diverse mTOR inhibitors, from rapalogs to novel agents and natural compounds, offer promising therapeutic strategies.
• Further research into selective mTOR inhibition holds potential for improved cancer treatment outcomes.